These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24595078)
1. IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. Malekzadeh M; Dehaghani AS; Ghaderi A; Doroudchi M Cancer Biomark; 2013 Jan; 13(6):417-25. PubMed ID: 24595078 [TBL] [Abstract][Full Text] [Related]
2. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. Zhang W; Wang L; Xin Z Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586 [TBL] [Abstract][Full Text] [Related]
3. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498 [TBL] [Abstract][Full Text] [Related]
4. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176 [TBL] [Abstract][Full Text] [Related]
5. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275 [TBL] [Abstract][Full Text] [Related]
6. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392 [TBL] [Abstract][Full Text] [Related]
7. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors. Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401 [TBL] [Abstract][Full Text] [Related]
8. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC; Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689 [No Abstract] [Full Text] [Related]
9. Assessment of Th17 lymphocytes and cytokine IL‑17A in epithelial ovarian tumors. Winkler I; Pyszniak M; Pogoda K; Semczuk A; Gogacz M; Miotla P; Adamiak A; Darmochwal-Kolarz D; Rechberger T; Tabarkiewicz J Oncol Rep; 2017 May; 37(5):3107-3115. PubMed ID: 28393233 [TBL] [Abstract][Full Text] [Related]
10. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis? Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024 [TBL] [Abstract][Full Text] [Related]
11. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528 [TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039 [TBL] [Abstract][Full Text] [Related]
13. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. Kan CW; Hahn MA; Gard GB; Maidens J; Huh JY; Marsh DJ; Howell VM BMC Cancer; 2012 Dec; 12():627. PubMed ID: 23272653 [TBL] [Abstract][Full Text] [Related]
14. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914 [TBL] [Abstract][Full Text] [Related]
15. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964 [TBL] [Abstract][Full Text] [Related]
16. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients. Li QL; Wang CJ; Qi P; Zhang YX Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of HOXC6 in Serous Ovarian Cancer. Tait DL; Bahrani-Mostafavi Z; Vestal CG; Richardson C; Mostafavi MT Cancer Invest; 2015; 33(7):303-11. PubMed ID: 26046583 [TBL] [Abstract][Full Text] [Related]
18. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939 [TBL] [Abstract][Full Text] [Related]
19. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels. Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232 [TBL] [Abstract][Full Text] [Related]
20. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Carbotti G; Orengo AM; Mezzanzanica D; Bagnoli M; Brizzolara A; Emionite L; Puppo A; Centurioni MG; Bruzzone M; Marroni P; Rossello A; Canevari S; Ferrini S; Fabbi M Int J Cancer; 2013 Jun; 132(11):2597-605. PubMed ID: 23169448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]